GILEAD SCIENCES - Dusseldorf Stock Exchang (GIS DU) stock market data APIs
€92.5168
2.12(2.3%)
as of July 4, 2025
Try our APIs with
free plan!
GILEAD SCIENCES - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.DU.
Prev. Close
92.5168
Open
94.6415
High
94.6415
Low
92.5168
52 wk Range
60.3725-109.5917
Market Cap
78 028 M
Dividends (Yield)
0.0273
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES - Dusseldorf Stock Exchang data using free add-ons & libraries
Get GILEAD SCIENCES - Dusseldorf Stock Exchang Fundamental Data
GILEAD SCIENCES - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get GILEAD SCIENCES - Dusseldorf Stock Exchang Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get GILEAD SCIENCES - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES - Dusseldorf Stock Exchang News
New
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc.�...
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
Company Logo The global chronic hepatitis B market is experiencing growth due to breakthroughs in diagnosis and treatment, including gene-editing and immune modulation therapies. With therapies advan...
Gilead extends gains after Supreme Court upheld an Obamacare provision
Investing.com -- The U.S. Supreme Court upheld a provision of the Affordable Care Act requiring insurers to cover preventive services, such as HIV prevention and cancer screenings, at no additional co...
This firm represents one of investing’s toughest moral debates
While many big drug companies do amazing things for humanity, they’re also often vilified for profiteering from their work. This month, New York-listed Gilead Sciences has, not for the first time, r...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
